公开(公告)号：US20180140700A1

公开(公告)日：2018-05-24

申请号：US15849018

申请日：2017-12-20

Applicant: Genentech, Inc.

Inventor： Gail Lewis Phillips ,  Deepak Sampath ,  Ingrid Wertz

IPC: A61K39/395 ,  A61K31/496 ,  A61K47/68 ,  C07K16/32 ,  A61P35/00 ,  G01N33/574

Abstract: The present invention is directed to a combination therapy involving an anti-HER2 antibody-drug conjugate and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a HER2-expressing cancer.

公开(公告)号：US09717730B2

公开(公告)日：2017-08-01

申请号：US15017315

申请日：2016-02-05

Applicant: Genentech, Inc.

Inventor： Kui Lin ,  Michelle Nannini ,  Elizabeth Punnoose ,  Deepak Sampath ,  Jeffrey Wallin ,  Premal Patel

IPC: A61K31/00 ,  A61K31/4745 ,  A61K31/495 ,  C07D239/70 ,  A61K31/517 ,  A61K31/437 ,  A61K31/496 ,  A61K31/58 ,  A61K31/282 ,  A61K31/337 ,  A61K31/4188 ,  A61K31/513 ,  A61K31/519 ,  A61K31/704 ,  A61K39/395 ,  C07D403/12 ,  A61K31/436 ,  A61K31/138 ,  A61K31/4166 ,  A61K31/555 ,  A61K31/7068 ,  C07K16/40 ,  A61K39/00

CPC classification number: A61K31/517 ,  A61K31/138 ,  A61K31/282 ,  A61K31/337 ,  A61K31/4166 ,  A61K31/4188 ,  A61K31/436 ,  A61K31/437 ,  A61K31/4745 ,  A61K31/495 ,  A61K31/496 ,  A61K31/513 ,  A61K31/519 ,  A61K31/555 ,  A61K31/58 ,  A61K31/704 ,  A61K31/7068 ,  A61K39/3955 ,  A61K2039/505 ,  C07D239/70 ,  C07D403/12 ,  C07K16/40 ,  A61K2300/00

Abstract: The invention provides combinations comprising a) compound of formula I: or a pharmaceutically acceptable salt thereof wherein R1, R2, R5, R10, and A have any of the values defined in the specification; and b) one or more agents selected from 5-FU, a platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38, capecitabine, temozolomide, paclitaxel, bevacizumab, pertuzumab, tamoxifen, rapamycin and lapatinib. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.

公开(公告)号：US09610289B2

公开(公告)日：2017-04-04

申请号：US14836827

申请日：2015-08-26

Applicant: Genentech, Inc.

Inventor： Michelle Nannini ,  Deepak Sampath

IPC: A61K31/505 ,  A61K31/517 ,  C07D239/70 ,  A61K31/437 ,  A61K31/496 ,  A61K31/58 ,  A61K31/282 ,  A61K31/337 ,  A61K31/4188 ,  A61K31/4745 ,  A61K31/513 ,  A61K31/519 ,  A61K31/704 ,  A61K39/395 ,  C07D403/12 ,  A61K31/436 ,  A61K31/138 ,  A61K31/4166 ,  A61K31/495 ,  A61K31/555 ,  A61K31/7068 ,  C07K16/40 ,  A61K39/00

CPC classification number: A61K31/517 ,  A61K31/138 ,  A61K31/282 ,  A61K31/337 ,  A61K31/4166 ,  A61K31/4188 ,  A61K31/436 ,  A61K31/437 ,  A61K31/4745 ,  A61K31/495 ,  A61K31/496 ,  A61K31/513 ,  A61K31/519 ,  A61K31/555 ,  A61K31/58 ,  A61K31/704 ,  A61K31/7068 ,  A61K39/3955 ,  A61K2039/505 ,  C07D239/70 ,  C07D403/12 ,  C07K16/40 ,  A61K2300/00

Abstract: The invention provides A combination of, a) a compound of Formula Ia: or a pharmaceutically acceptable salt thereof; and b) erlotinib or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a hyperproliferative disorder, such as cancer.

公开(公告)号：US20160279142A1

公开(公告)日：2016-09-29

申请号：US15080019

申请日：2016-03-24

Applicant: Genentech, Inc.

Inventor： Lori Friedman ,  Michelle Nannini ,  Deepak Sampath ,  Jeffrey Wallin

IPC: A61K31/553 ,  C12Q1/68 ,  A61K31/519

CPC classification number: A61K31/553 ,  A61K31/519 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N33/57415 ,  G01N33/57484 ,  G01N2333/912 ,  G01N2333/916 ,  G01N2800/52 ,  A61K2300/00

Abstract: Methods and compositions are provided for treating cancer in patients with a therapeutic combination comprising a therapeutically effective amounts of taselisib and palbociclib, or stereoisomers, geometric isomers, tautomers, or pharmaceutically acceptable salts thereof.

Abstract translation: 提供了用于治疗患有治疗性组合的癌症的方法和组合物，所述疗法组合包含治疗有效量的替莫西立和巴布西利或其立体异构体，几何异构体，互变异构体或其药学上可接受的盐。

公开(公告)号：US11590128B2

公开(公告)日：2023-02-28

申请号：US17834709

申请日：2022-06-07

Applicant: GENENTECH, INC. ,  HOFFMANN-LA ROCHE INC. ,  ABBVIE INC.

Inventor： Deepak Sampath ,  Christian Klein ,  Wayne John Fairbrother ,  Sari L. Heitner Enschede ,  Rod A. Humerickhouse ,  Andrew W. Roberts ,  John F. Seymour

IPC: A61K31/496 ,  A61K31/02 ,  A61K31/04 ,  A61K31/10 ,  A61K31/18 ,  A61K31/33 ,  A61K31/436 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/45 ,  A61K31/505 ,  A61K31/63 ,  A61K39/395 ,  A61K39/00

Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

公开(公告)号：US20220370441A1

公开(公告)日：2022-11-24

申请号：US17834709

申请日：2022-06-07

Applicant: GENENTECH, INC. ,  HOFFMANN-LA ROCHE INC. ,  ABBVIE INC.

Inventor： Deepak Sampath ,  Christian Klein ,  Wayne John Fairbrother ,  Sari L. Heitner Enschede ,  Rod A. Humerickhouse ,  Andrew W. Roberts ,  John F. Seymour

IPC: A61K31/496 ,  A61K31/18 ,  A61K31/10 ,  A61K31/04 ,  A61K31/02 ,  A61K31/33 ,  A61K31/437 ,  A61K31/45 ,  A61K31/4375 ,  A61K31/63 ,  A61K39/395 ,  A61K31/436 ,  A61K31/505

Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

公开(公告)号：US20220211696A1

公开(公告)日：2022-07-07

申请号：US17395366

申请日：2021-08-05

Applicant: GENENTECH, INC. ,  HOFFMANN-LA ROCHE INC. ,  ABBVIE INC.

Inventor： Deepak Sampath ,  Christian Klein ,  Wayne John Fairbrother ,  Sari L. Heitner Enschede ,  Rod A. Humerickhouse ,  Andrew W. Roberts ,  John F. Seymour

IPC: A61K31/496

Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

公开(公告)号：US10959993B2

公开(公告)日：2021-03-30

申请号：US15767914

申请日：2016-11-03

Applicant: Genentech, Inc. ,  Board of Regents, The University of Texas System

Inventor： Mark Merchant ,  Deepak Sampath ,  Marina Konopleva ,  Lina Han

IPC: A61K31/5365 ,  A61K31/497 ,  A61K31/4523 ,  A61K45/06 ,  A61K31/496 ,  A61P35/02

Abstract: The present invention is directed to a combination therapy involving a selective Bcl-2 inhibitor and a MEK inhibitor for the treatment of a patient in need of such a therapy. The patient in need of the combination therapy is suffering from cancer, such as acute myeloid leukemia.

公开(公告)号：US20180280408A1

公开(公告)日：2018-10-04

申请号：US15897032

申请日：2018-02-14

Applicant: Genentech, Inc.

Inventor： Marcia Belvin ,  Lori Friedman ,  Deepak Sampath ,  Jeffrey Wallin

IPC: A61K31/553 ,  A61K39/395 ,  G01N33/50 ,  C12Q1/6886 ,  A61K45/06 ,  A61K31/138 ,  A61K31/337 ,  A61K31/357 ,  A61K31/4196 ,  A61K31/437 ,  A61K31/4523 ,  A61K31/513 ,  A61K31/555 ,  A61K31/565 ,  A61K31/573 ,  A61K31/7068

Abstract: Methods and compositions are provided for treating hyperproliferative disorders in patients with a PI3K inhibitor, GDC-0032 as a single agent or in combination with chemotherapeutic agents.

公开(公告)号：US20160375033A1

公开(公告)日：2016-12-29

申请号：US15194859

申请日：2016-06-28

Applicant: Genentech, Inc.

Inventor： Kyle Edgar ,  Lori Friedman ,  Deepak Sampath ,  Kyung Song ,  Ingrid Wertz ,  Timothy Wilson

IPC: A61K31/553 ,  G01N33/68 ,  G01N33/574 ,  A61K31/565

CPC classification number: A61K31/553 ,  A61K31/138 ,  A61K31/337 ,  A61K31/357 ,  A61K31/4196 ,  A61K31/565 ,  A61K31/573 ,  A61K31/7068 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156 ,  G01N33/57415 ,  G01N33/57484 ,  G01N33/6848 ,  G01N2333/47 ,  G01N2500/10 ,  G01N2800/52 ,  A61K2300/00

Abstract: Taselisib (GDC-0032) induces the degradation of mutant-p110 alpha protein. Methods for selecting patients with mutant PI3K tumors for treatment with taselisib are described.

Abstract translation: Taselisib（GDC-0032）诱导突变型p110α蛋白的降解。 描述了选择患有Taselisib治疗的突变型PI3K肿瘤患者的方法。